Facilitating Alzheimer disease research recruitment
Joshua D Grill1, James E Galvin
1*Department of Neurology, David Geffen School of Medicine, Mary S. Easton Center for Alzheimer's Disease Research, UCLA, Los Angeles, CA †Department of Neurology, Psychiatry and Population Health, Alzheimer's Disease Center, New York University Langone Medical Center, New York, NY.
Alzheimer Disease and Associated Disorders
|December 11, 2013
Summary
Recruiting participants for Alzheimer disease (AD) research is difficult. This review explores strategies like community engagement and registries to improve enrollment and diversity in AD clinical trials.
Area of Science:
- Neuroscience
- Clinical Research
- Public Health
Background:
- Alzheimer disease (AD) research, including clinical trials and biomarker studies, faces significant enrollment challenges.
- Inadequate participant recruitment jeopardizes research validity, generalizability, and can exacerbate health disparities.
- Existing recruitment improvement methods lack consistent evidence of effectiveness and vary in resource requirements.
Purpose of the Study:
- To review methods for improving recruitment in AD research.
- To evaluate the supporting literature for various recruitment strategies.
- To share experiences from AD Research Centers regarding recruitment.
Main Methods:
- Literature review of AD research recruitment strategies.
- Analysis of evidence supporting or refuting these strategies.
- Discussion of community-based participatory research (CBPR) principles.
- Examination of participant registries for enhancing enrollment and diversity.
Main Results:
- Evidence for the effectiveness of many recruitment strategies is inconsistent or lacking.
- Community-based participatory research principles show promise for enhancing enrollment.
- Participant registries can improve research participation rates and sample diversity.
Conclusions:
- Effective recruitment methods are crucial for the success and validity of Alzheimer disease research.
- Community-based participatory research and participant registries are valuable tools for improving AD research enrollment and diversity.
- Further research is needed to establish the effectiveness of various recruitment strategies.
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35